Precigen (PGEN) Cash from Financing Activities (2012 - 2026)
Precigen (PGEN) posted quarterly Cash from Financing Activities of $109000.0 for Q1 2026, up 116.05% year-over-year from $50450.6 in Q1 2025, and up 121.21% quarter-over-quarter from -$514000.0 in Q4 2025.
Powered by 
Analysis
Precigen (PGEN) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Cash from Financing Activities for 15 consecutive years, with $109000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 116.05% year-over-year to $109000.0; the TTM figure through Mar 2026 stood at $90.8 million (down 17.35% YoY), while the FY2025 annual figure was $90.0 million, down 18.57% from the prior year.
- Cash from Financing Activities grew to $109000.0 in Q1 2026 per PGEN's latest filing, from -$514000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $93.0 million in Q3 2025 and bottomed at -$115.7 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged $5.4 million across 5 years, with a median of -$138000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 49558.97% — and 2023, when it jumped 27200.61%.
- Precigen's Cash from Financing Activities stood at -$39.3 million in 2022, then soared by 62.87% to -$14.6 million in 2023, then soared by 637.57% to $78.4 million in 2024, then sank by 100.66% to -$514000.0 in 2025, then surged by 121.21% to $109000.0 in 2026.
- Business Quant data shows PGEN's Cash from Financing Activities at $109000.0 in Q1 2026, -$514000.0 in Q4 2025, and $93.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | -33,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -33,000.00 |
| Mar 31, 2026 | 109,000.00 |
| Dec 31, 2025 | -514,000.00 |
| Sep 30, 2025 | 93.01 Mn |
| Jun 30, 2025 | -1.77 Mn |
| Mar 31, 2025 | -679,000.00 |
| Dec 31, 2024 | 78.40 Mn |
| Sep 30, 2024 | 32.13 Mn |
| Jun 30, 2024 | 52,000.00 |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | 44.17 Mn |
| Dec 31, 2022 | -39.28 Mn |
| Sep 30, 2022 | -115.73 Mn |
| Jun 30, 2022 | -113,000.00 |
| Mar 31, 2022 | -163,000.00 |
| Dec 31, 2021 | -110,000.00 |
| Sep 30, 2021 | 234,000.00 |
| Jun 30, 2021 | 23,000.00 |
| Mar 31, 2021 | 121.04 Mn |
| Dec 31, 2020 | -72,000.00 |